ArticleScientific reports2019
The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies.Zeitschrift fur medizinische Physik · 2026Review
- A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational Analysis of Key Parameters in Lutetium-177 PSMA Therapy.Annals of biomedical engineering · 2026Article
- The value of target-site physiologically-based pharmacokinetics for high-affinity small molecules: a mechanistic foundation for precision dosing in oncology and hematology.Cancer chemotherapy and pharmacology · 2026Article
- Leveraging [Clinical and translational science · 2026Article
- Second generation PSMA-targeted turn-on probe for imaging cargo release in prostate cancer cells.Bioorganic & medicinal chemistry letters · 2026Article
- Assessing PSMA Receptor Availability Using 68Ga-PSMA-11 PET/CT Following 177Lu-PSMA-617 Therapy Administration.Clinical nuclear medicine · 2026Article
- Intra-arterial HepaticCardiovascular and interventional radiology · 2026Article
- Recent Advances in Radiopharmaceuticals for Cancer Diagnosis and Therapy.Oncology research · 2026Review
- Feasibility study ofEJNMMI physics · 2025Article
- Preclinical Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Multi-scale computational modeling towards efficacy in radiopharmaceutical therapies while minimizing side effects: Modeling of amino acid infusion.PLoS computational biology · 2025Article
- Physiologically Based Pharmacokinetic Model of Tyrosine Kinase Inhibitors to Predict Target Site Penetration, with PET-Guided Verification.CPT: pharmacometrics & systems pharmacology · 2025Article
- Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling.Scientific reports · 2025Article
- Article
- Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Prostate Specific Membrane Antigen Expression in a Syngeneic Breast Cancer Mouse Model.Molecular imaging and biology · 2024Article
- A Comparison of Arterial Input Function Interpolation Methods for Patlak Plot Analysis ofIEEE transactions on medical imaging · 2024Article
- A Deep-Learning-Based Partial-Volume Correction Method for QuantitativeJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?European journal of nuclear medicine and molecular imaging · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations for PET/CT imaging and on the absorbed doses for therapy. A physiologically-based pharmacokinetic (PBPK) model for PSMA-specific ligands was implemented. Thirteen virtual patients with metastatic castration-resistant prostate cancer were analysed. Simulations were performed for different combinations of association rates k
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.